Benzodiazepines in schizophrenia: Prefrontal cortex atrophy predicts clinical response to alprazolam augmentation

World Journal of Biological Psychiatry

Volumn 3, Issue 4, 2002, Pages 221-224

  Seeley, William W ^a   Turetsky, Neil ^b   Reus, Victor I ^c   Wolkowitz, Owen M ^c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Private Practice   (Israel)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alprazolam; benzodiazepines; magnetic resonance imaging; prefrontal cortex; schizophrenia

Indexed keywords

ALPRAZOLAM; ANXIOLYTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ATROPHY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; SCHIZOPHRENIA;

ADOLESCENT; ADULT; ALPRAZOLAM; ANTI-ANXIETY AGENTS; ATROPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 0037795669     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970209150625     Document Type: Article

References (23)

1. Akbarian S, Kim JJ, Potkin SC, Hagman JO, Tafazzoli A, Bunney Jr WE, Jones EC (1995) Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 52:258-266.
2. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL (1991) Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001.
3. Bertolino A, Knable MB, Saunders RC, Callicot JH, Kolachana B, Mattay VS, Bachevalier J, Frank JA, Egan M, Weinberger DR (1999) The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia. Biol Psychiatry 45.
4. Brake WG, Flores G, Francis D, Meaney MJ, Srivastava LK, Gratton A (2000) Enhanced nucleus accumbens and plasma corticosterone stress responses in adult rats with neonatal excitotoxic lesions to the medial prefrontal cortex. Neuroscience 96:687-695.
5. Breier A, Wolkowitz OM, Pickar D (1991) Stress and schizophrenia. In: Tamminga CA, Schulz SC (eds) Advances in Neuropsychiatry and Psychopharmacology: Schizophrenia Research, Vol 1. Raven Press, Ltd., New York, pp 141-152.
6. Breier A, Davis OR, Buchanan RW, Moricle LA, Munson RC (1993) Effects of metabolic perturbation on plasma homovanillic acid in schizophrenia. Relationship to prefrontal cortex volume. Arch Gen Psychiatry 50:541-550.
7. Deutch AY (1993) Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease.) Neural Transm 91:197-221.
8. Fadda F, Argiolas A, Melis MR, Tissari AH, Onali PL, Gessa GL (1978) Stress-induced increase in 3, 4-dihydroxyphenylacetic acid (DOPAC) levels in the cerebral cortex and in n. accumbens: reversal by diazepam. Life Sci 23:2219-2224.
9. Finlay JM, Zigmond M| (1997) The effects of stress on central dopaminergic neurons: possible clinical implications. Neurochem Res 22:1387-1394.
10. Friedman L, Knutson L, Shurell M, Meltzer HY (1991) Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol Psychiatry 29:865-877.
11. Honer WC, Smith GN, Lapointe JS, MacEwan GW, Kopala L, Altman S (1995) Regional cortical anatomy and clozapine response in refractory schizophrenia. Neuropsychopharmacol 13:85-87.
12. Konicki PE, Kwon KY, Steele V, White J, Fuller M, Jurjus GJ, Jaskiw CE (2001) Prefrontal sulcal widening associated with poor treatment response to clozapine. Schiz Res 48:173-176.
13. Lauriello J, Mathalon DH, Rosenbloom M, Sullivan EV, Faustman WO, Ringo DL, Lim KO, Pfefferbaum A (1998) Association between regional brain volumes and clozapine response in schizophrenia. Biol Psychiatry 43:879-886.
14. Lewis DA, Pierri JN, Volk DW, Melchitsky DS, Woo TUW (1999) Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46:616-626.
15. Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC (1999) Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: focus on GABA content, GABA (A) receptor alpha-1 sububit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 93:441-448.
16. Rodriquez VM, Andree RM, Castejon MJP, Garcia EC, Delgado JLC, Vila FJR (1996) SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. Am J Psychiatry 153:1343-1346.
17. Schroder J, Bubeck B, Demisch S, Sauer H (1997) Benzodiazepine receptor distribution and diazepam binding in schizophrenia: an exploratory study. Psychiatry Res 68:125-131.
18. rd WJ, Rose RM (1999) Critical review of GABA'ergic drugs in the treatment of schizophrenia. J Clin Psychopharmacol 19:222-232.
19. Weinberger DR, Aloia MS, Goldberg TE, Berman KF (1995) The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosciences 6:419-427.
20. Wolkowitz OM, Pickar D (1991) Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 148:714-726.
21. Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D (1988) Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Arch Gen Psychiatry 45:664-671.
22. Wolkowitz OM, Bartko JJ, Pickar D (1990) Drug trials and heterogeneity in schizophrenia: The mean is not the end. Biol Psychiatry 28:1021-1025.
23. Wolkowitz OM, Turetsky N, Reus VI, Hargreaves W (1992) Alprazolam-neuroleptic treatment of schizophrenia: New findings, 18th Collegium Internationale Neuropsychopharmacologicum. Nice, France.